Suppr超能文献

总生存期短的骨髓瘤患者的T细胞表型和克隆性变化

T cell phenotype and clonality changes in myeloma patients with short overall survival.

作者信息

Behsen Alenka Djarmila, Vandsemb Esten Nymoen, Slørdahl Tobias Schmidt, Dybkær Karen, Jakobsen Maja Zimmer, Kashif Muhammad, Lund Johan, Luong Vincent, Olsnes Astrid Marta, Waage Anders, Sponaas Anne Marit, Misund Kristine

机构信息

Department of Clinical and Molecular Medicine, Norwegian University of Science and Technology, Trondheim, Norway.

Department of Hematology, St. Olavs Hospital, Trondheim, Norway.

出版信息

JCI Insight. 2025 Apr 22;10(11). doi: 10.1172/jci.insight.181096. eCollection 2025 Jun 9.

Abstract

Overall survival (OS) in multiple myeloma (MM) varies between a couple of months to more than 20 years, influenced by tumor characteristics, the tumor microenvironment (TME), and patient factors such as age and frailty. We analyzed sequential BM samples from 45 MM patients with OS less than 3 years versus more than 8 years using mass cytometry and bulk TCRβ sequencing. Patients with long OS demonstrated stability in the TME and T cell environments, while those with short OS had significant changes at relapse, including fewer T cells, increased Tregs, and more activated and exhausted CD8+ T cells. Notably, higher programmed cell death 1 expression in CD8+ T cells at diagnosis correlated with short OS. Additionally, short-OS patients exhibited a more monoclonal T cell environment at relapse, with abundance of hyperexpanded clones. These findings reveal distinct immune cell differences between patients with short and long OS.

摘要

多发性骨髓瘤(MM)患者的总生存期(OS)从几个月到20多年不等,受肿瘤特征、肿瘤微环境(TME)以及年龄和虚弱程度等患者因素影响。我们使用质谱流式细胞术和大量TCRβ测序分析了45例OS小于3年与大于8年的MM患者的连续骨髓样本。OS长的患者在TME和T细胞环境中表现出稳定性,而OS短的患者在复发时有显著变化,包括T细胞减少、调节性T细胞增加以及更多活化和耗竭的CD8+T细胞。值得注意的是,诊断时CD8+T细胞中程序性细胞死亡1表达较高与OS短相关。此外,OS短的患者在复发时表现出更单克隆的T细胞环境,有大量过度扩增克隆。这些发现揭示了OS短和长的患者之间不同的免疫细胞差异。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验